Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
Patient with advanced liver cancer (cancer that has spread to other parts of the body)
 continues to receive the study drug (G-202) even though patient no longer meets the criteria
 to be a part of the main treatment study. Patient's cancer responded well to receiving G-202
 in the main study and will receive G-202 at the same dose given in the main study.
Inclusion Criteria:

 -  History of hepatocellular carcinoma

 -  Participation in prior research study where G-202 was administered

 -  Tolerance of G-202 treatment

 -  Demonstration of stable disease

 Exclusion Criteria:

 -  Disease progression

 -  Occurrence of unacceptable toxicity